how this correlates with other tests or drug label? should we just abandon PD-1?

Thanks, [~Albert--Dekker--adikker@ ], for your comment. Per the authors, one limitation of this study is clinical correlates, which were based on one cohort. In the article, the authors wrote the following: "Based on the multivariable analysis (Table 2), the miRisk score is an independent significant predictor of OS in all three cohorts. Additionally, ECOG is associated with OS in the validation and control cohorts." Does anyone else have thoughts on the potential clinical implications of this blood-based miRNA signature? Please feel free to share.

Key Points
• Source: npj Precision Oncology
• Relevance: “We have traced the signature to a myeloid origin and performed miRNA target prediction to make a direct mechanistic link to the PD-L1 signaling pathway and PD-L1 itself. The miRisk score offers a potential blood-based companion diagnostic for immunotherapy that outperforms tissue-based PD-L1 staining.”
• The status quo for stratifying patient immunotherapy with PD-1/PD-L1 inhibitor class is via tumor (tissue-based) PD-L1 expression. PD-L1 is accurate, however, in about 30% of cases.
• “Response to immunotherapy is likely governed by the complex interplay between tumor and immune dependent factors, inherently limiting response prediction based on single biomarkers (e.g. PD-L1) or unilateral tumor-derived parameters (e.g. plasma tumor mutational burden (pTMB)),” the authors wrote. “Instead, integrating multiple omics covariates may offer a better reflection of this complexity and thus a more accurate evaluation of risk and benefit.”
• The authors leveraged miRNA profiles as a substitute for phenotypic inference into the tumor immune microenvironment (TME) and susceptibility to immunotherapy. The miRisk score probably reflects and synthesizes information from multiple peripheral immune sources, thus recapitulating the systemic immune status.
• A limitation of the current study is that the miRisk score as a predictor of patient OS has been validated only in a single independent patient cohort. “We acknowledge that the predictive versus prognostic nature of the miRisk score has not been definitively addressed,” they wrote.

any correlation with clinical outcomes.